This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
Emraclidine (CVL-231) is a selective positive allosteric modulator (PAM) of the cholinergic M4 muscarinic receptor and is the only selective…
molecule
2 weeks ago ●
1 min read
YCT529 (YourChoice) is a potential non-hormonal male contraceptive with impressive preclinical oral efficacy that is expected to enter clinical development…
molecule
2 weeks ago ●
4 mins read
IL-17 has been a hot target in immunology thanks to the clinical and commercial success of marketed anti-IL-17A and anti-IL-17RA…
molecule
2 weeks ago ●
2 mins read
Ziftomenib (KO-539) is an oral menin-MLL1 protein-protein interaction inhibitor being developed for acute myeloid leukemia (AML) by Kura Oncology. This…
molecule
2 weeks ago ●
3 mins read
Mavacamten is a first-in-class oral, selective, allosteric cardiac myosin inhibitor, discovered by Myokardia and acquired by BMS in 2020 in…
molecule
2 weeks ago ●
2 mins read
In 2022, Drug Hunter highlighted 120 Molecules of the Month with structures or stories that were published for the first…
Article
2 weeks ago ●
1 min read
Load More
